| Similar Articles |
|---|
 |
The Motley Fool
November 9, 2006
Brian Lawler |
Noven Might Be in a Purple Patch Investors in Noven shares might as well pay most of their attention to Shire, because as long as Daytrana does well, so too will Noven.   |
The Motley Fool
May 1, 2007
Brian Lawler |
Pay Attention to Noven The drug developer announced results from another quarter of strong growth. Revenue doubled versus the year-ago period as sales of its attention-deficit hyperactivity disorder patch, Daytrana, began to pick up. |
The Motley Fool
October 9, 2007
Brian Lawler |
Shire Slims Down, Slightly The U.K.-based pharmaceutical sells off some of its marketed drugs in order to focus more on its key ADHD franchises. |
The Motley Fool
February 26, 2007
Brian Lawler |
Shire's Busy Week Shire Pharmaceuticals announces year-end results, new regulatory approval, and another acquisition. |
The Motley Fool
October 30, 2006
Brian Lawler |
Building a Future Shire ADHD drugs are big for Shire now, but the long term isn't as clear. Investors, take note. |
The Motley Fool
June 30, 2008
Brian Orelli |
Johnson & Johnson Grows Up a Little Its Concerta for attention-deficit disorder is approved for use in adults. |
BusinessWeek
October 24, 2005
Gene G. Marcial |
Undivided Attention For An ADHD Battle Sales of Shire Pharmaceuticals' Adderall XR, the leading ADHD drug, are up. |
The Motley Fool
December 5, 2005
W.D. Crotty |
Cashing In on Noven's Drug Patch An FDA advisory panel recommends approval of Noven's patch for attention deficit hyperactivity. For now, investors might be put off by the company's lofty valuation of 55 times trailing earnings. |
The Motley Fool
July 12, 2007
Brian Lawler |
Noven's Novel Acquisition With JDS Pharmaceuticals, the company is moving toward more traditional oral drugs. Investors, take note. |
The Motley Fool
July 27, 2007 |
Shire's Got Focus: Fool by Numbers Revenue and guidance are up at Shire, led by improved sales of their ADHD drugs. |
BusinessWeek
August 22, 2005
Gene G. Marcial |
New River May Have A "Blockbuster" For ADHD New River Pharmaceuticals has yet to make a dime - but investors love it. |
The Motley Fool
February 26, 2007 |
Sales Up at Shire Pharmaceuticals: Fool by Numbers The drugmaker released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
May 25, 2011
David Williamson |
Pay Attention to Shire The British ADHD medicine maker is busy making big moves. |
The Motley Fool
August 19, 2004
Charly Travers |
1 Pill for Sleep, Attention Ailments? Cephalon gets some good news about its drug PROVIGIL. |
BusinessWeek
October 27, 2003
Catherine Arnst |
Attention Deficit: Not Just Kid Stuff Drugmakers are starting to target an overlooked group: Adults with ADHD. |
The Motley Fool
December 28, 2007
Brian Lawler |
Investors Wary on Noven Approval Noven Pharmaceuticals announces that the FDA has issued a tentative approval for one of its drugs, yet shares are trading lower since the news. Is the "tentative" status making investors jittery? |
The Motley Fool
November 21, 2008
Brian Orelli |
Manufacturing Pain Johnson & Johnson has plenty of it. |
BusinessWeek
March 27, 2006
Gene G. Marcial |
Cortex Draws A Bead On Hyperactivity When Cortex Pharmaceuticals disclosed on Mar. 8 that its lead drug, CX717, showed favorable results in Phase 2 trials for the treatment of adult ADHD, the stock jumped. |
The Motley Fool
October 9, 2006
Brian Lawler |
New Drug for New River An approvable letter from the FDA sends shares of New River Pharmaceuticals up. |
Chemistry World
June 23, 2014
Phillip Broadwith |
Shire fends off AbbVie takeover bid Shire is the latest pharmaceutical company to be targeted for a multi-billion dollar takeover deal from a firm looking to transfer its tax residence outside the US. |
American Family Physician
May 1, 2001 |
Learning About ADHD in Children ADHD, or attention-deficit/hyperactivity disorder, is a common health problem in children. Children with ADHD are hyperactive--they can't sit still. They are also impulsive and easily distracted. They have trouble coping at school and at home... |
The Motley Fool
August 28, 2008
Brian Orelli |
Me-Too Drugs: Are They Worth It? These drugs have less risk, but also usually bring less of a reward to the companies that make them. |
The Motley Fool
December 26, 2006
Brian Lawler |
Barely a Ripple for New River With New River's $2 billion market cap, no recurring revenues to speak of, and the terms of its partnership with Shire still uncertain, these shares are more than a tad too rich. |
InternetNews
June 15, 2011 |
Microsoft Puts Out 16 Patches in June Update More than half of the patches are labelled as 'critical' by Microsoft. |
American Family Physician
November 1, 2000 |
When Adults Have ADHD Attention-deficit/hyperactivity disorder is also called ADHD. People with ADHD are hyperactive or distracted most of the time. Even when they try to concentrate, they find it hard to pay attention... |
Pharmaceutical Executive
June 1, 2012 |
Raising the Stakes in CNS As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory. |
The Motley Fool
April 2, 2007
Brian Lawler |
Pain Therapeutics Pares Shares The small drugmaker announces a share buyback. |
The Motley Fool
August 20, 2007
Brian Lawler |
Are These Perfect Pharma Acquisitions? Weighing recent drug-industry deals' odds of success: AstraZeneca and MedImmune... Shire and New River Pharmaceuticals... Gilead and Myogen... |
InternetNews
December 14, 2010 |
Microsoft's Big Patch Tuesday, 17 Security Fixes Microsoft finishes out the year with one of the largest patch releases in its history. |
InternetNews
December 10, 2010
Stuart J. Johnston |
Microsoft Planning 17 Fixes for Patch Tuesday In its monthly security release, software giant advises IT managers to expect 17 individual patches, though only two are deemed critical, the most severe designation in Microsoft's rating system. |
InternetNews
June 3, 2010 |
Microsoft Alerts IT to Three 'Critical Patches Patch Tuesday will include ten patches ranging in importance that IT departments would be well-advised to check out. |
InternetNews
May 5, 2006
Ed Sutherland |
Microsoft Hoping For Smoother Patch Tuesday Microsoft plans next week to release three patches aimed at three software vulnerabilities in Windows and the software giant's Exchange e-mail server. |
Managed Care
June 2006 |
More Young Adults Prescribed ADHD Drugs The number of adults ages 20 to 44 prescribed attention deficit hyperactivity disorder medications increased about 140% from 2000 to 2005. This was even faster growth than the 82% reported for children. |
The Motley Fool
May 2, 2007
Mike Havrilla |
Consider Cortex New findings may give Cortex's ADHD drug the lift it needs. The news represents an excellent opportunity for speculative biotech investors |
InternetNews
November 5, 2009 |
Patch Tuesday Will Tackle Three 'Critical' Bugs Microsoft releases its monthly "heads up" for IT staffers on next week's bug-squishing party. |
InternetNews
January 6, 2011 |
Microsoft Plans One Critical Patch on Tuesday After keeping security administrators on the hop throughout December, Microsoft is planning a relatively tame January with its upcoming Patch Tuesday release. |
The Motley Fool
August 7, 2008
Brian Orelli |
The Next Pharma Acquisition The rate of mergers and acquisitions among drugmakers has reached a feverish pace lately, and doesn't show any signs of slowing down anytime soon. Take a look at some likely candidates. |
CIO
August 1, 2003
Bob Violino |
Patching Things Up The latest patch management tools can help reduce costs and increase reliability. |
Chemistry World
January 26, 2015
Phillip Broadwith |
Shire deepens rare disease focus with NPS buyout UK specialty pharmaceutical firm Shire has agreed to buy US biotech NPS Pharmaceuticals for $5.2 billion. |
The Motley Fool
October 8, 2007
Brian Lawler |
Noven's Acquisition Blues A recently acquired drug fails a late-stage clinical trial. Investors, take note. |
Chemistry World
November 11, 2013
Phillip Broadwith |
Shire will cut UK R&D to focus on rare diseases Shire Pharmaceuticals has begun an employee consultation process as it seeks to discontinue a significant proportion of research and development activities at its historic UK base in Basingstoke. |
Chemistry World
November 4, 2015
Phillip Broadwith |
Shire to buy cardiovascular specialist Dyax The deal gives Shire access to Dyax's portfolio of approved and developmental drugs for treating hereditary angioedema. |
The Motley Fool
October 30, 2007
Brian Orelli |
Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note. |
Managed Care
June 2004 |
Use of Attention-Deficit Medications Surges 369 Percent in Children Under 5 ADHD medication spending for pediatric patients outpaces antibiotics, allergy, and asthma treatments. |
Scientific American
July 2005
Gunjan Sinha |
Training the Brain Cognitive therapy as an alternative to ADHD drugs. |
American Family Physician
September 15, 2000 |
The Nicotine Patch How do I use the patch?... What do I need to tell my doctor before I use the patch?... My skin tingles under the patch. Is that normal?... Can I wear the patch in the shower?... What if the patch falls off?... |
American Family Physician
November 1, 2000
Searight, Burke & Rottnek |
Adult ADHD: Evaluation and Treatment in Family Medicine Attention-deficit/hyperactivity disorder (ADHD) affects 30 to 50 percent of adults who had ADHD in childhood. Accurate diagnosis of ADHD in adults is challenging and requires attention to early development and symptoms of inattention, distractibility, impulsivity and emotional lability... |
Pharmaceutical Executive
August 1, 2013
William Looney |
Succinctly Shire: An Interview with CEO Flemming Ornskov Shire's new CEO has a simple strategy for success: Set the pace on specialty medicines, spread the positive buzz and momentum of a growth stock, and seize the opportunity to innovate. |
